Clinical trials: Rhinitis Allergic
Seasonal Allergic Rhinitis
A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
The purpose of this study is to determine if two allergy medications (formulated azelastine and fluticasone product) are more effective than placebo or either medication alone (azelastine or fluticasone)
- Trial name
- NCT00740792
- Testing
- azelastine HCl/fluticasone propionate, azelastine Hcl, fluticasone propionate
- Where
- 39 sites in United States
- Volunteers
- 776 people
- Sponsor
- Meda Pharmaceuticals
Allergic Rhinitis
Omnaris Versus Levocetirizine Phase 4 Study
This i a comparison of the efficacy ciclesonide nasal spray and levocetirizine, alone and in combination.
- Trial name
- NCT01430260
- Testing
- Ciclesonide, Levocetirizine, Ciclesonide & Levocetirizine
- Where
- South Korea
- Volunteers
- 349 people
- Sponsor
- Handok Inc.
Rhinosinusitis, Asthma
Theophylline in Rhinitis
Allergic rhinitis and asthma are common respiratory diseases, which often coexist. The prevalence of allergic rhinitis in subjects with asthma is up to 80%, and the prevalence of asthma is 3-5 times greater in subjects with…
- Conditions
- Rhinosinusitis, Asthma, Allergic Rhinitis
- Trial name
- NCT01132781
- Testing
- Theophylline (Intervention Group)
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- University of East Anglia
Seasonal Allergic Rhinitis
The Effect of Nasal Carbon Dioxide (CO2) Used As-Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis
The purpose of this study is to evaluate the effect of as-needed treatment with nasal carbon dioxide in patients with Seasonal Allergic Rhinitis symptoms.
- Trial name
- NCT00917020
- Testing
- Nasal CO2
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Capnia, Inc.
Seasonal Allergic Rhinitis
The Effect of Nasal Carbon Dioxide (CO2) in the Symptomatic Treatment of Seasonal Allergic Rhinitis
The purpose of this study is to evaluate the effect of four times a day treatment with nasal carbon dioxide in patients with Seasonal Allergic Rhinitis symptoms.
- Trial name
- NCT00917111
- Testing
- Nasal CO2
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Capnia, Inc.
Rhinitis, Allergic, Perennial
Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)
The primary objective of the study was to characterize the difference in prepubescent growth velocity in children 3 to 9 years of age with perennial allergic rhinitis (PAR) treated with triamcinolone acetonide (TAA) nasal spray…
- Trial name
- NCT00449072
- Testing
- TAA-AQ, Nasacort® AQ, Claritin®
- Where
- United States
- Volunteers
- 299 people
- Sponsor
- Sanofi
Allergic Rhinitis, Asthma
Allergic Inflammation in Rhinitis Patients Following Nasal Allergen Challenge
Allergic rhinitis is a common condition caused by inflammation of nasal mucosa. The study was performed to gain information on this inflammation, including effect of intranasal corticosteroid treatment hereupon and potential…
- Trial name
- NCT01657097
- Testing
- INCS
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University of Aarhus
Seasonal Allergic Rhinitis
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
The purpose of this study is to determine if two allergy medications (azelastine and fluticasone) are more effective than placebo or either medication alone (azelastine or fluticasone)
- Trial name
- NCT00660517
- Testing
- MP29-02, azelastine Hcl, fluticasone propionate
- Where
- 7 sites in United States
- Volunteers
- 607 people
- Sponsor
- Meda Pharmaceuticals
Perennial Allergic Rhinitis
Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis
To demonstrate the effects of ciclesonide applied as a nasal aerosol and ciclesonide aqueous (AQ) nasal spray on hypothalamic-pituitary-adrenal axis.
- Trial name
- NCT01033825
- Testing
- Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, Ciclesonide Aqueous Nasal Spray 200 mcg
- Where
- 6 sites in United States
- Volunteers
- 310 people
- Sponsor
- Sumitomo Pharma America, Inc.
Perennial Allergic Rhinitis
Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)
The purpose of the study is to evaluate the effects of BDP HFA Nasal Aerosol on HPA-axis function.
- Trial name
- NCT01133626
- Testing
- Prednisone capsules, Beclomethasone dipropionate
- Where
- 3 sites in United States
- Volunteers
- 107 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Rhinitis, Allergic, Perennial and/or Seasonal
Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis
The primary objective was to evaluate the effect of a 6-week treatment with TAA-AQ (110 μg) and TAA-AQ (220 μg) once daily (QD) versus placebo on hypothalamic-pituitary-adrenal (HPA) axis function as measured by serum cortisol…
- Trial name
- NCT01154153
- Testing
- Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ), Claritin® Syrup
- Where
- 8 sites in United States
- Volunteers
- 140 people
- Sponsor
- Sanofi
Allergic Rhinitis, Perennial Allergic Rhinitis
A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
This is a 6-month multi-center, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of ciclesonide HFA nasal aerosol administered once-daily to male and female subjects 12 years or older…
- Trial name
- NCT00953147
- Testing
- Ciclesonide HFA 80 mcg, Ciclesonide HFA 160 mcg
- Where
- 45 sites in United States
- Volunteers
- 1,110 people
- Sponsor
- Sumitomo Pharma America, Inc.
Seasonal Allergic Rhinitis
Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older
This clinical research study will evaluate the safety and effectiveness of two doses of an investigational medication (ciclesonide nasal aerosol) for the treatment of subjects with of seasonal allergic rhinitis (SAR).
- Trial name
- NCT01010971
- Testing
- Ciclesonide HFA 160 μg, Ciclesonide HFA 80 μg
- Where
- 7 sites in United States
- Volunteers
- 671 people
- Sponsor
- Sumitomo Pharma America, Inc.
Perennial Allergic Rhinitis
A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
6-month safety extension study in subjects who have completed Study 060-633 (NCT00953147). Evaluating the long-term safety of ciclesonide HFA nasal aerosol 160 μg administered once-daily in patients with Perennial Allergic…
- Trial name
- NCT01067105
- Testing
- ciclesonide HFA 160 μg
- Where
- 44 sites in United States
- Volunteers
- 824 people
- Sponsor
- Sumitomo Pharma America, Inc.
Allergic Rhinitis
Azelastine Fluticasone Combination vs. Fluticasone
The purpose of this study is to see how a combination spray of azelastine and fluticasone (antihistamine and steroid) compares with a steroid nasal spray (fluticasone) alone in allergic rhinitis i.e.
- Trial name
- NCT00845598
- Testing
- Azelastine , fluticasone, Fluticasone propionate
- Where
- 2 sites in United Kingdom
- Sponsor
- University of Dundee
Allergic Rhinitis
Controlled Exposure to Diesel Exhaust in Subjects With Allergic Rhinitis
Proximity to traffic, particularly to diesel-powered heavy-duty vehicles, has been associated with inducing and enhancing allergies in children and adults.
- Trial name
- DALLER (NCT01617330)
- Testing
- Bronchoscopy
- Where
- Sweden
- Volunteers
- 14 people
- Sponsor
- University Hospital, Umeå
Perennial Allergic Rhinitis
A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis
The purpose of this study is to compare the effectiveness of an Investigational use of an allergy medication (MP03-33) used to treat perennial allergic rhinitis (PAR) to placebo (a nasal spray that contains no medicine).
- Trial name
- NCT01018862
- Testing
- Azelastine hydrochloride nasal spray 0.15%, Azelastine hydrochloride nasal spray 0.10%
- Where
- 39 sites in United States
- Volunteers
- 489 people
- Sponsor
- Meda Pharmaceuticals
Allergic Rhinitis, Rhinitis, Allergic, Seasonal
A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis
This study is an 8 day, randomised, double blind, 2-way crossover trial of repeat doses of intranasal GSK256066 and azelastine hydrochloride in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR).
- Trial name
- NCT00612118
- Testing
- GSK256066, azelastine hydrochloride
- Where
- Austria
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rhinitis, Allergic, Seasonal, Seasonal Allergic Rhinitis
Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber
This study is in patients with seasonal allergic rhinitis (SAR) and will compare the effect versus placebo of repeat doses of intranasal GSK256066 using the Vienna Challenge Chamber.
- Trial name
- NCT00430157
- Testing
- GSK256066
- Where
- Austria
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Rhinitis Allergic, Persistent
Evaluation of Safety of Levocetirizine in Routine Clinical Practice-non- Interventional Study
To evaluate over a period of 6 months the safety and the treatment satisfaction of newly prescribed levocetirizine in patients of age ≥ 2 years with persistent allergic rhinitis.
- Trial name
- NCT00598780
- Where
- United States
- Volunteers
- 7,870 people
- Sponsor
- UCB Pharma